Sold as Doca, Percorten. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Desoxycorticosterone Acetate (sold as Doca, Percorten), first approved Aug 17, 1939, with 0 new uses approved and 0 published complete response letters.
| Aug 17, 1939 | DocaNDA 1104 | Organon USA Inc | 1 | Discontinued |
| Dec 9, 1942 | PercortenNDA 5151 | Novartis | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis